Vivo Bio Tech Ltd Stock Price Today (NSE: VIVOBIOT)
Fundamental Score
Vivo Bio Tech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vivo Bio Tech Ltd share price today is ₹21.05, up +0.00% on NSE/BSE as of 30 March 2026. Vivo Bio Tech Ltd (VIVOBIOT) is a Small-cap company in the Biotechnology sector with a market capitalisation of ₹68.05 (Cr). The 52-week high for VIVOBIOT share price is ₹44.70 and the 52-week low is ₹22.90. At a P/E ratio of 16.64x, VIVOBIOT is currently trading below its industry average P/E of 51.82x. The company has a Return on Equity (ROE) of 5.68% and a debt-to-equity ratio of 0.58.
Vivo Bio Tech Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Vivo Bio Tech Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Vivo Bio Tech Share Price: A ROCE Efficiency Perspective
Within the Biotechnology sector, a critical, often overlooked, factor for long-term success is the efficient allocation of capital. Companies that can consistently generate higher returns on their capital employed are often better positioned to navigate market fluctuations and capitalize on growth opportunities. This analysis examines the financial health of Vivo Bio Tech Ltd, focusing on its Return on Capital Employed (ROCE). Currently, the Vivo Bio Tech share price stands at ₹28.469999, with a Price-to-Earnings (PE) ratio of 16.64 and a ROCE of 9.04%.
The 9.04% ROCE provides insight into how effectively Vivo Bio Tech is utilizing its capital to generate profits. A higher ROCE generally indicates stronger profitability and efficiency. However, the key is context. A deeper dive into the components that drive ROCE for Vivo Bio Tech Ltd – operating profit margins and capital turnover – is warranted to identify areas of strength and potential improvement. Comparing this figure with industry benchmarks and peer performance is crucial for a comprehensive assessment.
When compared to sector peers, the picture becomes clearer. Consider
Advanced Enzyme Technologies Ltd. While a detailed comparison requires a thorough examination of their financial statements, qualitative factors such as management quality and strategic vision can significantly impact operational efficiency and, consequently, ROCE. Are Vivo Bio Tech's management decisions optimizing capital allocation as effectively as those at Advanced Enzyme Technologies Ltd? This is a vital question to explore.A sustainable, high ROCE contributes significantly to a company's economic moat. In Vivo Bio Tech's case, a 9.04% ROCE, while respectable, suggests the company may not possess a particularly wide moat based solely on capital efficiency. The company's ability to reinvest profits at attractive rates of return and consistently improve this metric will be critical for long-term value creation and competitive advantage. Further investigation into the drivers of this ROCE is crucial to understand its potential for sustainable growth.
This financial analysis, focused on ROCE efficiency, is part of a broader 80-parameter fundamental audit of Vivo Bio Tech Ltd. It has been verified by Sweta Mishra. This analysis is observational and intended for informational purposes only. It does not constitute investment advice, and no buy or sell recommendations are made.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vivo Bio Tech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VIVOBIOT across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Operating Margins (39.41%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 16.64 vs Industry: 51.82)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (5.68%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.04%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-83.37%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-3.35% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-8.66% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-3.27% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (1.88x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-28.72 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vivo Bio Tech Ltd Financial Statements
Comprehensive financial data for Vivo Bio Tech Ltd including income statement, balance sheet and cash flow
About VIVOBIOT (Vivo Bio Tech Ltd)
Vivo Bio Tech Ltd is a pioneering force in preclinical research, providing comprehensive solutions for biotechnology and pharmaceutical innovation. With a steadfast commitment to s...cientific rigor and ethical practices, Vivo Bio Tech empowers its partners to navigate the complex landscape of drug development. The company's state-of-the-art facilities and expert team provide a seamless integration of services, from early-stage discovery to advanced preclinical testing. By leveraging cutting-edge technologies and innovative methodologies, Vivo Bio Tech accelerates the journey towards novel therapeutics, ultimately improving human health. Vivo Bio Tech offers an extensive suite of specialized services designed to meet the diverse needs of the industry. Core competencies include robust in vivo and in vitro studies that meticulously evaluate the safety and efficacy of novel compounds. Its focus extends to comprehensive pharmacokinetic and toxicokinetic profiling, genotoxicity assessments, and precise analytical services. The company maintains the highest standards of quality and compliance, ensuring that all research is conducted in accordance with global regulatory guidelines. This unwavering dedication to excellence allows Vivo Bio Tech to deliver reliable and reproducible data, bolstering the confidence of its partners. In addition to its core research services, Vivo Bio Tech is a trusted source for high-quality research models and resources. Its animal facility houses a variety of specific pathogen-free (SPF) laboratory animals, meticulously bred and maintained to ensure optimal health and genetic integrity. Vivo Bio Tech also specializes in the development of custom rodent models, tailored to specific research needs. Furthermore, the company offers stem cell products and specialized laboratory animal diets. This comprehensive approach allows Vivo Bio Tech to be a one-stop destination for researchers seeking to accelerate their scientific discoveries.
Company Details
Key Leadership
VIVOBIOT Share Price: Frequently Asked Questions
What is the current share price of Vivo Bio Tech Ltd (VIVOBIOT)?
As of 30 Mar 2026, 12:03 pm IST, Vivo Bio Tech Ltd share price is ₹21.05. The VIVOBIOT stock has a market capitalisation of ₹68.05 (Cr) on NSE/BSE.
Is VIVOBIOT share price Overvalued or Undervalued?
VIVOBIOT share price is currently trading at a P/E ratio of 16.64x, compared to the industry average of 51.82x. Based on this relative valuation, the Vivo Bio Tech Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of VIVOBIOT share price?
The 52-week high of VIVOBIOT share price is ₹44.70 and the 52-week low is ₹22.90. These values are updated daily from NSE/BSE price data.
What factors affect the Vivo Bio Tech Ltd share price?
Key factors influencing VIVOBIOT share price include quarterly earnings growth (Sales Growth: 8.89%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Vivo Bio Tech Ltd a good stock for long-term investment?
Vivo Bio Tech Ltd shows a 5-year Profit Growth of -3.27% and an ROE of 5.68%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.58 before investing in VIVOBIOT shares.
How does Vivo Bio Tech Ltd compare with its industry peers?
Vivo Bio Tech Ltd competes with major peers in the Biotechnology. Investors should compare VIVOBIOT share price P/E of 16.64x and ROE of 5.68% against the industry averages to determine competitive standing.
What is the P/E ratio of VIVOBIOT and what does it mean?
VIVOBIOT share price has a P/E ratio of 16.64x compared to the industry average of 51.82x. Investors pay ₹17 for every ₹1 of annual earnings.
How is VIVOBIOT performing according to Bull Run's analysis?
VIVOBIOT has a Bull Run fundamental score of 16/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does VIVOBIOT belong to?
VIVOBIOT operates in the Biotechnology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Vivo Bio Tech Ltd share price.
What is Return on Equity (ROE) and why is it important for VIVOBIOT?
VIVOBIOT has an ROE of 5.68%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Vivo Bio Tech Ltd generates profits from shareholders capital.
How is VIVOBIOT debt-to-equity ratio and what does it indicate?
VIVOBIOT has a debt-to-equity ratio of 0.58, which indicates moderate leverage that should be monitored.
What is VIVOBIOT dividend yield and is it a good dividend stock?
VIVOBIOT offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Vivo Bio Tech Ltd shares.
How has VIVOBIOT share price grown over the past 5 years?
VIVOBIOT has achieved 5-year growth rates of: Sales Growth -3.35%, Profit Growth -3.27%, and EPS Growth -8.66%.
What is the promoter holding in VIVOBIOT and why does it matter?
Promoters hold 35.16% of VIVOBIOT shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Vivo Bio Tech Ltd.
What is VIVOBIOT market capitalisation category?
VIVOBIOT has a market capitalisation of ₹68 crores, placing it in the Small-cap category.
How volatile is VIVOBIOT stock?
VIVOBIOT has a beta of N/A. A beta > 1 suggests the Vivo Bio Tech Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is VIVOBIOT operating profit margin trend?
VIVOBIOT has a 5-year average Operating Profit Margin (OPM) of 39.41%, indicating the company's operational efficiency.
How is VIVOBIOT quarterly performance?
Recent quarterly performance shows Vivo Bio Tech Ltd YoY Sales Growth of 8.89% and YoY Profit Growth of -83.37%.
What is the institutional holding pattern in VIVOBIOT?
VIVOBIOT has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Vivo Bio Tech Ltd stock.